WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015031654) SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION AND TREATING CONDITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/031654    International Application No.:    PCT/US2014/053223
Publication Date: 05.03.2015 International Filing Date: 28.08.2014
IPC:
A61K 38/00 (2006.01)
Applicants: CYTONICS CORPORATION [US/US]; 555 Heritage Drive, Suite 115 Jupiter, FL 33458 (US)
Inventors: HANNA, Lewis; (US).
LAUGHLIN, John, David; (US).
BROWNING, Shawn, Robert; (US)
Agent: McANDREW, Christopher; (US)
Priority Data:
61/871,009 28.08.2013 US
61/990,522 08.05.2014 US
61/990,524 08.05.2014 US
Title (EN) SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION AND TREATING CONDITIONS
(FR) SYSTÈMES, COMPOSITIONS ET PROCÉDÉS DE TRANSPLANTATION ET DE TRAITEMENT D'ÉTATS PATHOLOGIQUES
Abstract: front page image
(EN)Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.
(FR)L'invention concerne des systèmes et des procédés de purification et de concentration d'alpha-2-macroglobuline (A2M) autologue provenant de sang total et/ou de A2M recombinante. L'invention concerne également des procédés de traitement de lésions avec A2M. L'invention concerne également des procédés d'utilisation d'A2M en combinaison avec d'autres traitements (par exemple plaquettes et autres facteurs de croissance), en plus de combinaisons avec des médicaments ou des excipients exogènes. L'invention concerne également un procédé de production d'un type sauvage d'A2M recombinante ou de variantes de celui-ci, la région d'attaque ayant été modifiée pour améliorer les caractéristiques d'inhibition d'A2M et/ou prolonger la demi-vie de la protéine afin de traiter des lésions.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)